Alexion’s Phase 3 Japanese trial results of acoramidis show consistency with ATTRibute-CM trial
The results from the Japanese trial were on par with the ATTRibute-CM trial in terms of survival rates,…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
05 Feb 24
The results from the Japanese trial were on par with the ATTRibute-CM trial in terms of survival rates,…
05 Feb 24
Nitisinone capsules are exclusively available through Optime Care, a specialised pharmacy committed to assisting patients dealing with rare…
05 Feb 24
TLANDO is approved by the FDA as a testosterone replacement therapy
02 Feb 24
WellSky will use Google Cloud’s secure cloud technologies, advanced data analytics tools, machine learning capabilities, and its enterprise-ready…
02 Feb 24
The deal involves Fountain Valley Regional Hospital, Lakewood Regional Medical Center, Los Alamitos Medical, Placentia-Linda Hospital, and other…
02 Feb 24
BST02 has received approval from the FDA for Phase I/II clinical trial in October 2023 and has also…
02 Feb 24
Sanofi to receive a 12-month right of first negotiation (ROFN) to explore collaboration opportunities spanning multiple indications, including…
01 Feb 24
The three-year collaboration is aimed at advancing the digitalisation and technology to advance medical dermatology and develop next-generation…
01 Feb 24
The company will return the licensing rights of the drug and terminate its post-marketing confirmatory ENVISION trial after…
01 Feb 24
Tyruko biosimilar to treat adults with highly active relapsing remitting multiple sclerosis (RRMS)